Drugs pricing row: 4 pharma firms move HC against govt order

Image
Press Trust of India New Delhi
Last Updated : Aug 02 2013 | 7:35 PM IST
Four pharma firms today moved the Delhi High Court challenging government's new drug pricing order that asked them to slash prices of certain medicines.
The companies were also told to replace stocks in the market with those carrying reduced prices within 45 days of new price notification.
A bench headed by Acting Chief Justice B D Ahmed asked the Centre not to take coercive steps against the firms - Macleods Pharmaceuticals Limited, Emcure Pharmaceuticals ltd, Laborate Pharmaceuticals India Ltd and Micro Labs Limited.
Firms like Cipla Ltd, which had approached the court earlier, have challenged the 2013 Drug Price Control Order (DPCO), issued by the National Pharmaceutical Pricing Authority (NPPA).
The DCPO had ordered reduction of prices of some medicines within 45 days of issuance of the notification and that the decreased prices be made effective on drugs already in market.
The deadline for implementation of the notification ended on July 29.
"The counsel for the petitioners shall also file copies of the agreements entered into with CNF agents/stockists/ distributors, if any, within two weeks," the bench said, adding the pharama firms will also have to give details of medicines "manufactured or sold".
Meanwhile, the Indian Drug Manufacturers Association today also moved the court against the DCPO order. The plea would be heard on August 5.
Earlier, the court had granted the same interim relief to Cipla Ltd by asking the Centre not to take coercive steps against it. Cipla has challenged the DCPO order asking it to reduce prices of its 125 drugs within 45 days of issuance of the notification.
The Ministry of Chemicals and Fertilisers, had on May 15, through NPPA issued a notification to implement the DPCO asking pharma companies to reduce prices of 348 medicines.
The DPCO also asked them to replace stocks in the market with those carrying reduced maximum retail price within 45 days of the new price notification by the NPPA.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 02 2013 | 7:35 PM IST

Next Story